TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

[1]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[2]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[3]  S. Srivastava,et al.  Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.

[4]  D. Turner,et al.  ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer , 2008, Expert review of anticancer therapy.

[5]  M. Rubin,et al.  TMPRSS2-ETS fusion prostate cancer: biological and clinical implications , 2007, Journal of Clinical Pathology.

[6]  I. Mills,et al.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor , 2007, EMBO reports.

[7]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[8]  V. Srikantan,et al.  Silencing of lactotransferrin expression by methylation in prostate cancer progression , 2007, Cancer biology & therapy.

[9]  J. Witte.  Multiple prostate cancer risk variants on 8q24 , 2007, Nature Genetics.

[10]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[11]  D. Yee,et al.  Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.

[12]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[13]  C. Bloomfield,et al.  High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.

[15]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[16]  A. Seth,et al.  ETS transcription factors and their emerging roles in human cancer. , 2005, European journal of cancer.

[17]  A. Seth.  Transcription factors in cancer , 2005 .

[18]  Thomas Werner,et al.  The next generation of literature analysis: Integration of genomic analysis into text mining , 2005, Briefings Bioinform..

[19]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[20]  Guido Marcucci,et al.  Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.

[21]  I. Kola,et al.  Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. , 2004, Gene.

[22]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[23]  T. Libermann,et al.  PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.

[24]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[25]  M. Groudine,et al.  Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter , 1992, Molecular and cellular biology.